Cancer
Cancer Ongoing 2021 North Shore NSW

ARANOTE

This study will assess the efficacy and safety of darolutamide in combination with standard androgen deprivation therapy (ADT) in patients with metastatic hormone sensitive prostate cancer.

Trial overview

Disease
Prostate cancer
Topic
ARANOTE
Description
Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer.
Eligibility criteria
  • Metastatic Hormone Sensitive Prostate Cancer
  • Within 12 weeks of starting ADT 
Study details

There is a screening period of 4 weeks to assess suitability for the trial. This is a randomised study with a ratio of 2:1 received the study therapy.  While on treatment there will be regular blood tests and scans to monitor progress. At completion of treatment the study will continue to follow your progress.

Further information

For more information regarding this clinical trial click here.

Location

North Shore NSW